Clinical investigation of cefuzonam in patients over 65 years old with biliary tract infections

Naoaki Tanno, Masaru Koizumi, Tooru Shimosegawa, Takayoshi Toyota, Hitoshi Rin, Keisuke Oota, Mizuo Kobari, Akihiko Ishida, Atsushi Miyazaki, Waichi Sato, Masahide Abe, Horoyoshi Onodera, Akio Yago, Tadahiro Suzuki, Hidetoshi Hirakawa, Tooru Matsuda, Shinichi Iketani, Norihiro Suzuki, Kouki Eda

研究成果: Article査読

抄録

We performed a multicenter clinical trial of cefuzonam (CZON) to evaluate its efficacy and safety in 21 patients over 65 years old with biliary tract infections. CZON was intravenously administered (2~4 g/day) to 11 patients with acute cholecystitis, 8 patients with acute cholangitis and 2 patients with acute cholecystitis plus cholangitis. Seven patients were concurrently treated by biliary drainage. The following results were obtained. 1) The overall clinical efficacy rate was 100%. 2) Bacteriological efficacy was assessed in 4 patients. Bacterial eradication was observed in 3 patients, and bacterial decrease was seen in 1 patient. 3) The clinical adverse effect, skin eruption, which was observed in only 1 patient (5%), was mild and transient. 4) The clinical usefulness rate was 100%. 5) The concentration of CZON in the bile 1 hour after intravenous injection of 1 g of the drug was very favorable, 588. 8±276. 9μg/ml (mean in 5 patients). The serum concentration of CZON 1 hour after intravenous injection of 1 g of the drug was 64.7±16.3μg/ml. We conclude that CZON is very effective and safe in patients over 65 years old with biliary tract infections.

本文言語English
ページ(範囲)1104-1112
ページ数9
ジャーナルChemotherapy
41
10
DOI
出版ステータスPublished - 1993
外部発表はい

ASJC Scopus subject areas

  • 薬理学(医学)
  • 感染症
  • 薬理学
  • 創薬
  • 腫瘍学

フィンガープリント

「Clinical investigation of cefuzonam in patients over 65 years old with biliary tract infections」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル